|
| Press Releases |
|
 |
|
| Wednesday, March 23, 2022 |
|
|
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities |
| Singapore Exchange-listed Alset International Ltd (SGX Stock Code: 40V) ("Alset", the "Company" or together with its subsidiaries, the "Group) wishes to announce that the Company has plans to embark on cryptocurrency mining business through its subsidiary Alset Mining Pte. Ltd. ("Alset Mining"). more info >> |
|
| Monday, February 21, 2022 |
|
|
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option |
| Alset Capital Acquisition Corp. (the "Company") announced on February 3, 2022 the closing of its initial public offering of 7,500,000 units at $10.00 per unit (the "Offering"). more info >> |
|
| Monday, October 5, 2020 |
|
|
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc. |
| Document Security Systems, Inc. today announced its wholly owned subsidiary Impact BioMedical, Inc. ("Impact BioMedical") has formed a new wholly owned subsidiary, Innate Immune, Inc. ("Innate Immune"), to initiate efficacy testing of a pancoronavirus vaccine, a special type of vaccine designed to protect against multiple coronaviruses. more info >> |
|
| Friday, September 18, 2020 |
|
|
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance |
| Document Security Systems, Inc. (NYSE American: DSS) today announced its wholly owned subsidiary Impact BioMedical, Inc., through its subsidiary Global BioLife, Inc., completed efficacy testing of its proprietary 3F Antiviral Biofragrance at a biosafety level 3 containment facility at an independent university. more info >> |
|
| Friday, July 31, 2020 |
|
|
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. ("Impact"), announced today the initiation of Quantum, their research program designed to solve the impending pharmaceutical patent cliff threat. more info >> |
|
| Wednesday, June 24, 2020 |
|
|
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that they proved in vitro success of Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. more info >> |
|
| Wednesday, June 17, 2020 |
|
|
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and Discovery Group Sciences ("GRDG"), conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. ("Vilotos"), was published in the peer-reviewed scientific journal Molecules on June 11, 2020. more info >> |
|
| Monday, June 1, 2020 |
|
|
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc., would like to update its stakeholders on its suite of antiviral and medical technologies. more info >> |
|
| Friday, April 24, 2020 |
|
|
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts |
| SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced recently that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). more info >> |
|
| Wednesday, March 18, 2020 |
|
|
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak |
| Singapore Exchange-listed Singapore eDevelopment Limited has announced that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("GRDG"), recently conducted molecular docking studies, utilizing advanced computational models, which indicate Linebacker and Equivir successfully inhibit infection of SARS-CoV-2, the virus responsible for the COVID-19 outbreak. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
New HKTDC Chairman Frederick Ma keen to promote Hong Kong as best partner for global enterprises
Jun 10, 2025 22:28 HKT/SGT
|
|
|
爆款IPO前瞻：「香水第一股」穎通控股強勢登場！港股IPO再現黃金賽道 龍頭勢掀「嗅覺經濟」新浪潮
Jun 10, 2025 19:10 HKT/SGT
|
|
|
爆款IPO前瞻：“香水第一股”颖通控股强势登场！港股IPO再现黄金赛道 龙头势掀“嗅觉经济”新浪潮
Jun 10, 2025 19:10 HKT/SGT
|
|
|
U.S. Polo Assn. Returns as Official Apparel and Jersey Partner for Chestertons Polo in the Park in Downtown London
Jun 10, 2025 19:00 HKT/SGT
|
|
|
Supercomputer Fugaku retains first place worldwide in Graph500 rankings
Jun 10, 2025 19:47 JST
|
|
|
ダイムラートラック、三菱ふそう、日野、トヨタ、三菱ふそうと日野の統合に関する最終合意を締結
Jun 10, 2025 16:30: JST
|
|
|
聯想控股副總裁于浩：在技術變革中錨定「長期主義」
Jun 10, 2025 15:37 HKT/SGT
|
|
|
联想控股副总裁于浩：在技术变革中锚定"长期主义"
Jun 10, 2025 15:28 HKT/SGT
|
|
|
Ai sẽ là người đầu tiên ghi danh vào lịch sử với tư cách là Nhà Vô Địch Thế Giới đầu tiên?!
Jun 10, 2025 14:00 HKT/SGT
|
|
|
Siapakah yang akan mengukir nama dalam sejarah sebagai "Juara Dunia Pertama"!
Jun 10, 2025 14:00 HKT/SGT
|
|
|
Siapakah yang akan mengukir namanya dalam sejarah sebagai “Juara Dunia Pertama”!
Jun 10, 2025 14:00 HKT/SGT
|
|
|
誰將成為名留青史的「初代世界冠軍」！
Jun 10, 2025 14:00 HKT/SGT
|
|
|
UK MOD Signs Protector Support Contract with GA-ASI
Jun 10, 2025 06:00 HKT/SGT
|
|
|
SRKay Consulting Group Releases Research Report: 'From Legal Frameworks to Successful Operations'--A Strategic Playbook for India Market Entry
Jun 9, 2025 17:00 HKT/SGT
|
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025
Jun 9, 2025 12:52 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
